Oscar Tahuahua, Medical Oncology fellow at the National Cancer Institute of Mexico, shared on X about a recent paper by Richard Y. Ebright et al. published in Cancer Discovery:
“RAS Inhibition: Response and Resistance
– Primary (10–20%): KEAP1, PI3K, TP53, SMARCA4 mutations.
– Acquired (~60%): KRAS muts (25–30%), RTKs (20–25%), PI3K (10–15%), MYC, EMT and MAPK pathway.
Rational combos and next-gen RAS inhibitors are key.”
Response and Resistance to RAS Inhibition in Cancer
Authors: Richard Y. Ebright et al
Learn more about RAS pathway in cancer on OncoDaily.